Want to see ENVB full AI Analyst Report?
ENVB Stock Chart & Stats
$3.72
-$0.12(-23.95%)
At close: 4:00 PM EST
$3.72
-$0.12(-23.95%)
Day’s Range― - ―
52-Week Range$1.26 - $17.63
Previous CloseN/A
Volume362.16K
Average Volume (3M)781.31K
Market Cap
$4.68M
Enterprise Value-$1.98
Total Cash (Recent Filing)$4.91M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.34
Shares Outstanding3,681,884
10 Day Avg. Volume899,153
30 Day Avg. Volume781,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetMaintaining no debt removes interest obligations and lowers fixed financial burden, preserving cash runway for R&D and trials. For a clinical-stage biotech, absence of leverage reduces bankruptcy risk and increases optionality for partnerships or equity financings over the next several months.
Management Incentive AlignmentUpdating long-term equity awards with multi-year vesting aligns executives and directors with multi-year clinical milestones, improving retention and governance. Stronger alignment supports disciplined decision-making on development priorities and potential licensing or partnership negotiations.
Clinical-stage, Platform FocusA platform targeting neuroplastogenic therapies addresses large, persistent unmet needs in mental health. If clinical programs prove efficacious and safer than alternatives, the platform could generate multiple assets and long-term partnering/licensing opportunities that sustain growth beyond near-term financing cycles.
Bears Say
No Revenue & Persistent LossesAbsence of operating revenue combined with multi-million-dollar net losses forces reliance on external capital to fund development. Over 2-6 months this elevates dilution and funding risk, constrains strategic choices, and makes progress contingent on successful financing or milestone-driven partner deals.
High Cash Burn / Weak Cash GenerationSustained negative operating and free cash flow indicates the company is consuming capital faster than generating it. Rising burn narrows runway, increases the frequency and size of required raises, and elevates execution risk for clinical programs absent material cost reductions or new funding sources.
Limited Balance-sheet FlexibilityA small equity base and modest assets reduce the firm's ability to absorb setbacks or fund extended trials internally. This structural constraint increases bargaining weakness in partner negotiations and likelihood of dilutive financings, which can impede long-term program continuity if trial timelines extend.
Enveric Biosciences News
ENVB FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was $1.26 and its highest was $17.63 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is $4.68M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 25 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on May 15, 2026. The company reported -$1.082 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 3,681,884 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -$1.082 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.747%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in ENVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
GT Biopharma
―
Artelo Biosciences
―
Ownership Overview
16.62% Insiders
0.22% Mutual Funds
0.46% Other Institutional Investors
81.30% Public Companies and
Individual Investors